CO2020009524A2 - Formulación de adenovirus del grupo b - Google Patents
Formulación de adenovirus del grupo bInfo
- Publication number
- CO2020009524A2 CO2020009524A2 CONC2020/0009524A CO2020009524A CO2020009524A2 CO 2020009524 A2 CO2020009524 A2 CO 2020009524A2 CO 2020009524 A CO2020009524 A CO 2020009524A CO 2020009524 A2 CO2020009524 A2 CO 2020009524A2
- Authority
- CO
- Colombia
- Prior art keywords
- adenovirus
- group
- formulation
- glycerol
- ethanol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción proporciona una formulación líquida adecuada para un adenovirus del grupo B, que comprende: a) un adenovirus del grupo B, tal como el adenovirus del grupo B competente para replicación, b) 15 a 25 % v/v de glicerol, por ejemplo 16, 17, 18, 19, 20, 21 % v/v de glicerol; y c) 0.1 a 1.5 % v/v de etanol, por ejemplo 0.2-1 %, tal como 1 % v/v de etanol; y d) un tampón, y e) opcionalmente un aminoácido, en donde el pH de la formulación está en el intervalo de 8.0 a 9.6, y uso del mismo en el tratamiento, en particular en el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801614.7A GB201801614D0 (en) | 2018-01-31 | 2018-01-31 | Formulation |
| PCT/EP2019/052398 WO2019149829A1 (en) | 2018-01-31 | 2019-01-31 | Group b adenovirus-containing formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020009524A2 true CO2020009524A2 (es) | 2020-08-21 |
Family
ID=61558316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0009524A CO2020009524A2 (es) | 2018-01-31 | 2020-07-30 | Formulación de adenovirus del grupo b |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20210121512A1 (es) |
| EP (1) | EP3746128A1 (es) |
| JP (1) | JP2024045278A (es) |
| KR (1) | KR20200115525A (es) |
| CN (1) | CN111727062A (es) |
| AU (1) | AU2019214397A1 (es) |
| BR (1) | BR112020014248A2 (es) |
| CA (1) | CA3088350A1 (es) |
| CL (1) | CL2020001821A1 (es) |
| CO (1) | CO2020009524A2 (es) |
| EA (1) | EA202091318A1 (es) |
| GB (1) | GB201801614D0 (es) |
| IL (1) | IL276011B (es) |
| MX (1) | MX2020007495A (es) |
| PH (1) | PH12020551057A1 (es) |
| SG (1) | SG11202005746RA (es) |
| WO (1) | WO2019149829A1 (es) |
| ZA (1) | ZA202003615B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016005170A (es) | 2013-10-25 | 2017-02-02 | Psioxus Therapeutics Ltd | Adenovirus oncoliticos armados con genes heterologos. |
| KR20240032177A (ko) | 2015-04-30 | 2024-03-08 | 싸이오서스 테라퓨틱스 엘티디. | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| WO2022040319A2 (en) * | 2020-08-18 | 2022-02-24 | New York Genome Center, Inc. | Methods and compositions for inhibiting viral infection |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CN114601838B (zh) * | 2022-04-29 | 2023-10-27 | 广东龙帆生物科技有限公司 | 一种azd8055在制备用于抗腺病毒感染的药物中的用途 |
| CN117618549A (zh) * | 2022-08-09 | 2024-03-01 | 康希诺生物股份公司 | 一种基于黑猩猩腺病毒载体疫苗液体制剂及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU778894B2 (en) * | 1999-04-09 | 2004-12-23 | Centelion S.A.S. | Composition for the preservation of infectious recombinant adenoviruses |
| US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| CN105431157A (zh) * | 2013-06-14 | 2016-03-23 | 普赛奥克苏斯治疗公司 | 用于b型腺病毒的给药方案及制剂 |
| KR20240032177A (ko) * | 2015-04-30 | 2024-03-08 | 싸이오서스 테라퓨틱스 엘티디. | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
-
2018
- 2018-01-31 GB GBGB1801614.7A patent/GB201801614D0/en not_active Ceased
-
2019
- 2019-01-31 WO PCT/EP2019/052398 patent/WO2019149829A1/en unknown
- 2019-01-31 EP EP19706388.6A patent/EP3746128A1/en active Pending
- 2019-01-31 EA EA202091318A patent/EA202091318A1/ru unknown
- 2019-01-31 CA CA3088350A patent/CA3088350A1/en active Pending
- 2019-01-31 MX MX2020007495A patent/MX2020007495A/es unknown
- 2019-01-31 IL IL276011A patent/IL276011B/en unknown
- 2019-01-31 BR BR112020014248-4A patent/BR112020014248A2/pt not_active IP Right Cessation
- 2019-01-31 KR KR1020207022489A patent/KR20200115525A/ko active Search and Examination
- 2019-01-31 AU AU2019214397A patent/AU2019214397A1/en not_active Abandoned
- 2019-01-31 US US16/965,549 patent/US20210121512A1/en active Pending
- 2019-01-31 CN CN201980008189.XA patent/CN111727062A/zh active Pending
- 2019-01-31 SG SG11202005746RA patent/SG11202005746RA/en unknown
-
2020
- 2020-06-17 ZA ZA2020/03615A patent/ZA202003615B/en unknown
- 2020-07-08 CL CL2020001821A patent/CL2020001821A1/es unknown
- 2020-07-09 PH PH12020551057A patent/PH12020551057A1/en unknown
- 2020-07-30 CO CONC2020/0009524A patent/CO2020009524A2/es unknown
-
2024
- 2024-01-22 JP JP2024007320A patent/JP2024045278A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019214397A1 (en) | 2020-08-13 |
| ZA202003615B (en) | 2021-09-29 |
| GB201801614D0 (en) | 2018-03-14 |
| CA3088350A1 (en) | 2019-08-08 |
| MX2020007495A (es) | 2020-11-12 |
| IL276011A (en) | 2020-08-31 |
| SG11202005746RA (en) | 2020-08-28 |
| PH12020551057A1 (en) | 2021-08-23 |
| KR20200115525A (ko) | 2020-10-07 |
| CL2020001821A1 (es) | 2020-11-06 |
| JP2024045278A (ja) | 2024-04-02 |
| WO2019149829A1 (en) | 2019-08-08 |
| EA202091318A1 (ru) | 2020-11-13 |
| JP2021512054A (ja) | 2021-05-13 |
| BR112020014248A2 (pt) | 2020-12-15 |
| CN111727062A (zh) | 2020-09-29 |
| IL276011B (en) | 2022-08-01 |
| US20210121512A1 (en) | 2021-04-29 |
| EP3746128A1 (en) | 2020-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009524A2 (es) | Formulación de adenovirus del grupo b | |
| CL2023000555A1 (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
| CL2020002866A1 (es) | Compuestos de heteroaril tetracíclicos | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
| PE20200006A1 (es) | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap | |
| ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
| ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| CL2020002797A1 (es) | Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| AR114313A1 (es) | Material portador para la liberación de uno o varios agentes activos en una formulación para el cuidado del hogar | |
| AR113901A1 (es) | Uso tópico y entrega de microorganismos oxidantes de amoniaco | |
| CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
| BR112022008558A2 (pt) | Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso | |
| DOP2019000228A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| CL2020003209A1 (es) | Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas | |
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CL2018000391A1 (es) | Combinaciones farmacéuticas y su uso | |
| AR106739A1 (es) | Uso de una cantidad terapéuticamente eficaz de un derivado clostridial para la preparación de una composición farmacéutica para el tratamiento de la incontinencia urinaria | |
| CL2019001550A1 (es) | Fenytoina tópica para uso en el tratamiento del dolor neuropático periférico. | |
| UY37731A (es) | Formulación de alcohol de estearilo |